PharmaCyte Biotech (NASDAQ:PMCB) Posts Quarterly Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) issued its quarterly earnings results on Monday. The company reported ($0.10) EPS for the quarter, Zacks reports.

PharmaCyte Biotech Price Performance

NASDAQ PMCB remained flat at $1.58 during trading on Monday. 1,528 shares of the company’s stock traded hands, compared to its average volume of 24,252. The stock has a market capitalization of $10.85 million, a PE ratio of 2.98 and a beta of -0.25. PharmaCyte Biotech has a 1-year low of $1.39 and a 1-year high of $2.58. The business’s 50-day simple moving average is $1.65 and its 200 day simple moving average is $1.70.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.